参松养心胶囊联合比索洛尔治疗围绝经期心律失常的临床观察

Shensong Yangxin Capsule Combined Bisoprolol in Treatment of Perimenopausal Arrhythmia

目的:观察参松养心胶囊联合比索洛尔治疗围绝经期心律失常的临床疗效及安全性。方法:将60例围绝经期心律失常患者随机分为治疗组与对照组,治疗组30例采用参松养心胶囊与比索洛尔联合治疗,对照组30例采用单纯比索洛尔治疗,服药8周,观察两组患者的临床疗效a及安全性。结果:临床症状改善率治疗组83.3%,对照组66.7%,治疗组优于对照组(P<0.05);24 h动态心电图两组治疗后早搏数量与治疗前自身比较均有显著减少(P<0.05),组间比较无显著差异(P>0.05);24 h动态心电图两组治疗后平均心率与治疗前自身比较均有显著减少(P<0.05),组间比较无显著差异(P>0.05)。两组治疗过程中均无不良反应。结论:参松养心胶囊联合比索洛尔治疗围绝经期心律失常安全有效。

Objective ： To observe theclinical efficacyand safety of Shensong YangxinCapsule combinedbisoprolol in thetreatment of perimenopausal arrhythmia. Methods ： Divide 60 patientsof perimenopausalsyndrome into treatmentgroup and control group by the way of random. The treatmentgroup＇ s 30patients were treated withShensong YangxinCapsulecom- bined withbisoprolol and the control group＇ s 30 patientswere treated with a simplebisoprolol. After 8 weeks, observethe clinicalefficacy and safety. Results ：The improvement rate of clinical symptoms was 83.3% in treatment group and 66.7% in control groupand the treatment group was better than control group （ P 〈 0. 05 ）. On the aspects of 24 h Holter, the premature contraction of the two groups was significantly reduced after treatment （ P 〈 0. 05 ） and there was no significant difference between the two groups （P 〉 0. 05 ）. After treatment, the average heart rate of two groups of 24 h Hoher was significantly reduced （ P 〈 0. 05 ）. There was no significant difference between the groups （ P 〉 0. 05 ）. Both groupshad noadverse reactionsduring treatment. Conclusion ： Shensong YangxinCapsule combined with bisoprolol in treatment of perimenopausal arrhythufia was safe and effective.